humburger icon
A circle of white paper dolls holding hands on a green background


Home > Study Groups > Antiemetics



Florian Scotté, MD, PhD

Mary Lou Affronti


Mary Lou Affronti, DNP, RN, MHSc, ANP, FAAN

Mission and Goals

The Antiemetics Study Group was originally established as a subcommittee of MASCC to address the control of nausea and vomiting induced by chemotherapy and radiotherapy. At the 1995 MASCC Annual Meeting in Luxembourg, the group organized a consensus conference on the use of antiemetics and identified eight major issues that served as the basis for the Consensus Conference held in Perugia, Italy, 28-29 April 1997. Results were published in the ESMO journal, Annals of Oncology (Ann Oncol.1998; 9: 811-819).

In the following years, the study group has worked on practice-changing programs such as the MASCC Antiemesis Tool development, globally used for the patient’s self-assessment of nausea and vomiting issues; and guidelines updates.

The different ones, provided joint or not with ESMO are highlighted in the table below.

Year Society Location Steering Committee Publications
1997 MASCC Perugia Gralla RJ, Roila F, Tonato M Support Care Cancer: 1998 (12)
Ann Oncol: 1998 (1)
2004 MASCC Perugia Gralla RJ, Roila F, Tonato M Support Care Cancer: 2005 (11)
Ann Oncol: 2006 (1)
2009 MASCC/ESMO Perugia Gralla RJ, Tonato M, Roila F, Herrstedt J. Support Care Cancer: 2011 (11)
Ann Oncol: 2010 (1)
2015 MASCC/ESMO Copenhagen Aapro MS, Gralla RJ, Herrstedt J, Roila F Molassiotis A Support Care Cancer: 2017 (10)
Ann Oncol: 2016 (1)
2022 MASCC/ESMO Toronto Herrstedt J, Clark-Snow R, Ruhlmann C, Jordan K, Scotté F Support Care Cancer: 2023 (10)
ESMO Open: 2023 (1)

The Antiemetics Study Group is facing evolution of anticancer treatments, comprehension of individual risk factors, patient’s involvement in cancer education and evolutions of patient pathways. New members are always welcome to share their vision with global leaders on the topic.

How to Join

To join a study group, you must be a MASCC member. Members can belong to up to three study groups. 


Evidence-based clinical practice guidelines created by the Antiemetics Study Group